A detailed history of Amalgamated Bank transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,766 shares of ALLO stock, worth $5,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,766
Previous 2,766 -0.0%
Holding current value
$5,780
Previous $6,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$2.92 - $5.63 $12,839 - $24,755
-4,397 Reduced 61.38%
2,766 $12,000
Q4 2023

Feb 06, 2024

SELL
$2.28 - $3.5 $1,876 - $2,880
-823 Reduced 10.31%
7,163 $23,000
Q2 2023

Aug 11, 2023

SELL
$4.53 - $6.74 $1,177 - $1,752
-260 Reduced 3.15%
7,986 $39,000
Q1 2023

May 02, 2023

SELL
$4.92 - $8.21 $9,574 - $15,976
-1,946 Reduced 19.09%
8,246 $41,000
Q3 2022

Nov 09, 2022

BUY
$10.32 - $17.28 $1,021 - $1,710
99 Added 0.98%
10,192 $110,000
Q2 2022

Aug 15, 2022

BUY
$6.78 - $12.28 $5,037 - $9,124
743 Added 7.95%
10,093 $115,000
Q1 2022

Jun 30, 2022

SELL
$7.65 - $15.29 $5,630 - $11,253
-736 Reduced 7.3%
9,350 $85,000
Q4 2021

Feb 15, 2022

SELL
$13.13 - $24.52 $1,286 - $2,402
-98 Reduced 0.96%
10,086 $150,000
Q3 2021

Oct 29, 2021

SELL
$21.01 - $27.64 $14,517 - $19,099
-691 Reduced 6.35%
10,184 $262,000
Q2 2021

Aug 16, 2021

BUY
$23.49 - $35.8 $75,144 - $114,524
3,199 Added 41.68%
10,875 $284,000
Q1 2021

May 13, 2021

SELL
$25.79 - $39.02 $19,342 - $29,265
-750 Reduced 8.9%
7,676 $271,000
Q4 2020

Feb 12, 2021

BUY
$25.24 - $43.45 $1,161 - $1,998
46 Added 0.55%
8,426 $212,000
Q3 2020

Oct 30, 2020

BUY
$32.38 - $44.96 $20,010 - $27,785
618 Added 7.96%
8,380 $316,000
Q2 2020

Aug 10, 2020

BUY
$18.39 - $54.04 $142,743 - $419,458
7,762 New
7,762 $332,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $301M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.